Lumasonix

Lumasonix is a medical device company commercializing hybrid ultrasound and photoacoustic systems for early and accurate detection of cancers at microscopic and macro levels. Cancer cells start circulating in the blood stream long before the primary tumor becomes detectable by conventional methods. Early detection of CTCs is a valuable clinical tool to evaluate prognosis and to help formulate effective treatment plans. The Lumasonix Blood Cell Analyzer is a label-free automated cytometry system that non-destructively distinguishes, counts, sizes, and, determines the morphology and internal structure of individual cells using light and ultrasound. Our proprietary cytometry technology works without fluorescent reagents, doesn't rely on any specific biomarker and individually profiles each cell; helping track cancer cells as they mutate over time for monitoring disease progression and therapy effectiveness. Our tumor margin analysis technology enables breast surgeons to quickly and non-destructively examine the excised tissues in the OR during the lumpectomy procedures, thereby improving the clinical outcomes for patients at lower overall costs. Our breast imaging technology non-invasively detects cancers in dense breasts and accurately distinguishes healthy tissue from cysts, benign and malignant tumors without requiring invasive tissue biopsies. We appreciate your interest and welcome your questions about our technology.

• Employees 1
• Founded 2011
• Annual Revenue $394000